References: |
Product Reference:
?Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo: J.S. Sebolt-Leopold, et al.; Nat. Med. 5, 810 (1999)
?Specificity and mechanism of action of some commonly used protein kinase inhibitors: S.P. Davies, et al.; Biochem. J. 351, 95 (2000)
?Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352: A.M. Delaney, et al.; Mol. Cell. Biol. 22, 7593 (2002)
?Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1: M.S. Squires, et al.; Biochem. J. 366, 673 (2002)
?CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK): L.F. Allen, et al.; Semin. Oncol. 30, 105 (2003) (Review)
?The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines: R.R. Mattingly, et al.; J. Pharmacol. Exp. Ther. 316, 456 (2006)
? |